OBJECTIVE: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy. PATIENTS AND METHODS: All 22 patients included in this report were seen at Mayo Clinic in Rochester, Minnesota, between August 1, 2008, and August 1, 2011, for evaluation of unexplained chronic diarrhea and enteropathy while taking olmesartan. Celiac disease was ruled out in all cases. To be included in the study, the patients also had to have clinical improvement after suspension of olmesartan. RESULTS: The 22 patients (13 women) had a median age of 69.5 years (range, 47-81 years). Most patients were taking 40 mg/d of olmesartan (range, 10-40 mg/d). The clinical presentation was of chronic diarrhea and weight loss (median, 18 kg; range, 2.5-57 kg), which required hospitalization in 14 patients (64%). Intestinal biopsies showed both villous atrophy and variable degrees of mucosal inflammation in 15 patients, and marked subepithelial collagen deposition (collagenous sprue) in 7. Tissue transglutaminase antibodies were not detected. A gluten-free diet was not helpful. Collagenous or lymphocytic gastritis was documented in 7 patients, and microscopic colitis was documented in 5 patients. Clinical response, with a mean weight gain of 12.2 kg, was demonstrated in all cases. Histologic recovery or improvement of the duodenum after discontinuation of olmesartan was confirmed in all 18 patients who underwent follow-up biopsies. CONCLUSION: Olmesartan may be associated with a severe form of spruelike enteropathy. Clinical response and histologic recovery are expected after suspension of the drug.
OBJECTIVE: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy. PATIENTS AND METHODS: All 22 patients included in this report were seen at Mayo Clinic in Rochester, Minnesota, between August 1, 2008, and August 1, 2011, for evaluation of unexplained chronic diarrhea and enteropathy while taking olmesartan. Celiac disease was ruled out in all cases. To be included in the study, the patients also had to have clinical improvement after suspension of olmesartan. RESULTS: The 22 patients (13 women) had a median age of 69.5 years (range, 47-81 years). Most patients were taking 40 mg/d of olmesartan (range, 10-40 mg/d). The clinical presentation was of chronic diarrhea and weight loss (median, 18 kg; range, 2.5-57 kg), which required hospitalization in 14 patients (64%). Intestinal biopsies showed both villous atrophy and variable degrees of mucosal inflammation in 15 patients, and marked subepithelial collagen deposition (collagenous sprue) in 7. Tissue transglutaminase antibodies were not detected. A gluten-free diet was not helpful. Collagenous or lymphocytic gastritis was documented in 7 patients, and microscopic colitis was documented in 5 patients. Clinical response, with a mean weight gain of 12.2 kg, was demonstrated in all cases. Histologic recovery or improvement of the duodenum after discontinuation of olmesartan was confirmed in all 18 patients who underwent follow-up biopsies. CONCLUSION:Olmesartan may be associated with a severe form of spruelike enteropathy. Clinical response and histologic recovery are expected after suspension of the drug.
Authors: N Patey-Mariaud De Serre; C Cellier; B Jabri; E Delabesse; V Verkarre; B Roche; A Lavergne; J Brière; L Mauvieux; M Leborgne; J P Barbier; R Modigliani; C Matuchansky; E MacIntyre; N Cerf-Bensussan; N Brousse Journal: Histopathology Date: 2000-07 Impact factor: 5.087
Authors: T P Chorzelski; E H Beutner; J Sulej; H Tchorzewska; S Jablonska; V Kumar; A Kapuscinska Journal: Br J Dermatol Date: 1984-10 Impact factor: 9.302
Authors: Marcus Teo; Stephen Chung; Lauri Chitti; Cuong Tran; Stamatiki Kritas; Ross Butler; Adrian Cummins Journal: J Gastroenterol Hepatol Date: 2004-08 Impact factor: 4.029
Authors: Thomas R Ziegler; Concepción Fernández-Estívariz; Li H Gu; Michael W Fried; Lorraine M Leader Journal: Gastroenterology Date: 2003-06 Impact factor: 22.682
Authors: E V Marietta; A M Nadeau; A K Cartee; I Singh; A Rishi; R S Choung; T-T Wu; A Rubio-Tapia; J A Murray Journal: Aliment Pharmacol Ther Date: 2015-10-01 Impact factor: 8.171
Authors: Andrea Marco-Marqués; Ana Sanahuja-Martinez; Marta Maia Bosca-Watts; Joan Tosca-Cuquerella; Pilar Mas-Mercader; Veronica Andrade-Gamarra; Francisco Mora-Miguel Journal: Am J Gastroenterol Date: 2015-10 Impact factor: 10.864
Authors: Karl Mårild; Benjamin Lebwohl; Peter H R Green; Joseph A Murray; Jonas F Ludvigsson Journal: Mayo Clin Proc Date: 2015-06 Impact factor: 7.616
Authors: Benjamin Lebwohl; Martin J Blaser; Jonas F Ludvigsson; Peter H R Green; Andrew Rundle; Amnon Sonnenberg; Robert M Genta Journal: Am J Epidemiol Date: 2013-10-11 Impact factor: 4.897
Authors: Ruby Greywoode; Eric D Braunstein; Carolina Arguelles-Grande; Peter H R Green; Benjamin Lebwohl Journal: Mayo Clin Proc Date: 2014-07-11 Impact factor: 7.616
Authors: Kamran Rostami; David Aldulaimi; Geoffrey Holmes; Matt W Johnson; Marie Robert; Amitabh Srivastava; Jean-François Fléjou; David S Sanders; Umberto Volta; Mohammad H Derakhshan; James J Going; Gabriel Becheanu; Carlo Catassi; Mihai Danciu; Luke Materacki; Kamran Ghafarzadegan; Sauid Ishaq; Mohammad Rostami-Nejad; A Salvador Peña; Gabrio Bassotti; Michael N Marsh; Vincenzo Villanacci Journal: World J Gastroenterol Date: 2015-03-07 Impact factor: 5.742